A teenager was diagnosed as paranoid schizophrenic by Cedars-Sinai, then again by Mayo Clinic. His furnace was poisoning him. It took John Kelley's data about 20 minutes to find it. In this episode, Jonathan W. Buckley sits down with John Kelley, Chairman of CereHealth Corp and the iLLUME Ai platform - and, twenty years ago, the CEO and Chairman of McData Corp when Jonathan worked in its marketing organization. John explains why a Vietnam-era draftee watching friends come home with Agent Orange exposure, PTSD, and misdiagnoses decided in 2009 that the same data informatics Google and Amazon used to predict purchases could predict what was actually wrong inside a person's brain. He walks through the "patients like me" cohort model built on roughly 4,800 referred patients, why traumatic brain injury became the company's specialty, and how carbon monoxide binds to the iron in the basal ganglia and starves it of dopamine - the mechanism two of America's best hospitals missed. The harder story is the go-to-market one. Pharma, insurance, and health systems - the three constituencies John assumed would embrace better diagnostics - all resisted, for rational reasons he lays out plainly. The VA, which should have been the natural ally, never engaged. Osteopathic physicians became the earliest adopters over MDs because they were trained to look at the whole system rather than the symptom. The company cleared the FDA in 120 days under the 21st Century Cures Act, immediately in Theranos's wake, got in front of four national carriers and Medicare, and then COVID arrived in March 2020 and took the momentum with it. Today the business has pivoted away from clinical services entirely, licensing its analytics engine as $2-4M enterprise contracts. John closes with the part most guests won't say out loud: after seven acquisitions across ten boards, he's not sure he was the right investor for this one - because he underestimated the resistance, and that's a due-diligence lesson, not a bad-luck story. Chapters00:00 The show, and how Jonathan and John met at McData01:56 Data informatics, Agent Orange, and the 2009 thesis03:24 "Patients like me" - the core idea04:32 Brought in as investor and chair, and the loss that changed the role06:58 4,800 patients, cohorts, and why TBI became the specialty08:46 Why pharma, insurance, and health systems all resisted11:10 The VA that should have been an ally12:33 Who said yes first: the non-siloed clinicians16:03 Why DOs became early adopters over MDs19:14 A Mission Viejo teenager, Cedars-Sinai, and Mayo21:45 Carbon monoxide, the basal ganglia, and a furnace flue24:18 Cash-pay reality, pro bono work, and suicide ideation26:13 FDA clearance in 120 days, right after Theranos28:12 Four carriers, Medicare, then COVID30:59 The pivot to iLLUME Ai and $2-4M licensing contracts33:18 Micro-targeting DOs and riding thought-leader credibility36:39 What he'd tell you about investing outside your specialty Guest: John Kelley, Chairman, CereHealth Corp. Previously CEO and Chairman of McData Corp, a NASDAQ 100 company. He has served on ten public and private-equity/venture-backed boards, seven of which reached acquisition. Watch the full episode on YouTube: https://www.youtube.com/watch?v=EnElZDxyGow Connect with John Kelley: https://www.linkedin.com/in/johnkelley3/CereHealth: https://www.linkedin.com/company/cerehealthiLLUME Ai: https://illumeai.com Subscribe on YouTube, Spotify, or Apple Podcasts for new conversations with early-stage tech founders and CEOs. See how The Artesian Network helps founders get established and reach scale: https://www.artesiannetwork.com/?utm_source=podcast&utm_medium=referral&utm_campaign=ep26&utm_content=shownotes
